Suven Pharmaceuticals
quarterly
yearly
| Particulars | Jun '21 | Sep '21 | Dec '21 | Mar '22 | Jun '22 |
|---|---|---|---|---|---|
| Revenue | 263.80 | 300.99 | 391.59 | 363.85 | 338.80 |
| Expenses | 158.19 | 188.39 | 216.07 | 217.25 | 199.42 |
| EBITDA | 105.61 | 112.60 | 175.52 | 146.60 | 139.38 |
| EBIT | 96.62 | 103.42 | 165.01 | 136.18 | 127.88 |
| Profit Before Tax | 132.92 | 133.93 | 239.46 | 161.28 | 148.96 |
| Net Profit | 105.08 | 96.98 | 160.07 | 91.67 | 107.54 |
| Financial Ratios | |||||
| Operating Profit Margin | 40.04% | 37.41% | 44.82% | 40.29% | 41.14% |
| Net Profit Margin | 39.83% | 32.22% | 40.88% | 25.19% | 31.74% |
| Earning Per Share (Diluted) | 4.13 | 3.81 | 6.29 | 3.60 | 4.22 |
| Dividends Per Share | NA | 1.00 | 1.00 | NA | NA |
